Critical Care

, 19:P369 | Cite as

Continuous blood glucose monitoring reduces the risk to ICU patients

  • KP Mulavisala
  • J Norrie
  • B Crane
  • N Barwell
Open Access
Poster presentation


Continuous Glucose Monitoring Blood Glucose Monitoring Absolute Relative Difference Intermittent Measurement Glycemic Management 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


GlySure Limited (Abingdon, UK), has developed a continuous intravascular glucose monitoring system (CIGMS) to simplify the application of hospital protocols for optimal glucose control at the point of care. We have previously reported on the early


achieved in cardiac patients [1] and MICU patients [2]. This initial success has been sustained and demonstrated in further patient groups. We have now reached the point where we can conjecture upon the regular application of the GlySure CIGMS in day-to-day ICU practice. This in turn prompts the question, 'How effective will continuous blood glucose data prove in such routine use?' Using actual case data, we have shown how comparing the mean absolute relative difference (MARD) and integration of the area under the curve (AUC) from the continuous glucose monitoring and intermittent measurement can be used to measure patient risk.


The analysis used aggregated case data generated from our recent clinical trials, where a GlySure sterile, single-use sensor and dedicated monitoring system was used to measure the blood glucose concentration in patients continuously and in real time. The measurement of risk was compared using the MARD, an accepted error calculation tool, and the AUC was calculated using an AUC analysis software program.


When MARD from the GlySure sensor and intermittent measurement using the hospital's existing protocol was compared, the measure of risk to the patient (that is, the uncertainty regarding the patient's absolute blood glucose status) for the GlySure sensor was 50.5% lower than the intermittent measurement. The results also showed that as the variability of the BG data increases, the benefit of continuous monitoring increases by significantly reducing patient risk. The continuous monitoring reduces the patient's risk by 88%, 73%, and 69% respectively in high, medium and low variability situations.


It is more and more evident that continuous glucose technology will be instrumental in driving safe and effective glucose management protocols that will support more consistent glycemic management standards within ICUs and across institutions.


  1. 1.
    Mulavisala KP, Gopal PB, Crane B: ISICEM. 2014, 442-[]Google Scholar
  2. 2.

Copyright information

© Mulavisala et al.; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • KP Mulavisala
    • 1
  • J Norrie
    • 2
  • B Crane
    • 3
  • N Barwell
    • 3
  1. 1.CARE HospitalsHyderabadIndia
  2. 2.SumStats LtdEdinburghUK
  3. 3.GlySure LtdAbingdonUK

Personalised recommendations